The Rhythm | Issue 19
Issue 19 | Week of 10 August 2026
No major cardiology congress fell this week. The strongest evidence came directly from European Heart Journal's advance articles, spanning pregnancy history, pharmacogenomics, diet, real-world heart failure practice, and cardio-oncology.
Cardiology Intelligence Briefing: the case for granularity
This week's papers shared one move: take a category clinicians treat as uniform and break it apart. An adverse pregnancy outcome is not one thing: risk differs according to when it occurs, whether it recurs, and what happens in subsequent pregnancies.1 ACE inhibitor cough, often treated as unpredictable patient susceptibility, gains a striking new genetic link through neurotensin-NTSR1 signalling.2 And ultra-processed food may be too broad a label on its own, with individual markers such as colouring agents and sweeteners carrying meaningfully different strengths of association with incident hypertension.3
None of that immediately changes what happens in clinic on Monday. The paper that comes closest is about delivery rather than discovery. In Japan, guideline-recommended heart failure care became substantially more consistent between 2013 and 2019–21, while one-year mortality was 26.7% lower in the later cohort.4 The lesson is less glamorous but more actionable: outcomes may improve not only by finding better treatments, but by getting proven ones to more of the patients who need them.
Oncology supplied the week's warning about pushing granularity too far. Across seventeen trials, Bruton's tyrosine kinase inhibitors carried a pooled signal for non-fatal ischaemic events real enough to survive pooling, yet not real enough to hold up when either half of the composite was tested alone.5 Breaking categories apart can expose clinically useful differences that broad labels conceal. It can also expose how fragile an apparent signal becomes under closer inspection. This week offered examples of both.
